Show
Sort by
-
Phase 3 study of ibrutinib as first-line treatment in older patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) : a 4-year follow-up from the RESONATE-2 study
-
Improvement in hematologic function, disease burden/symptoms with ibrutinib in older treatment-naive (TN) patients with chronic lymphocytic leukemia (CLL) in phase 3 RESONATE-2 (TM)
-
Improvement in quality of life and well-being in older patients with treatment-naive (TN) CLL : results from the randomized phase 3 study of ibrutinib (IBR) versus chlorambucil (CLB) (resonate-2™)
-
International, randomized phase 3 study results : Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM))
-
Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naive (TN) CLL/SLL (RESONATE-2 (TM))
-
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia